Background {#Sec1}
==========

Antimicrobial resistance (AMR) is considered a major health threat. The consequences of multidrug-resistant (MDR) bacterial infections including high morbidity and mortality and economic loss have been well documented in many studies \[[@CR1]--[@CR3]\]. Colonization by MDR bacteria is considered a potential source of cross-transmission to other patients \[[@CR4]--[@CR6]\]. Moreover, colonization by MDR bacteria was found to be an independent risk factor for developing subsequent MDR bacterial infections in previous studies \[[@CR5], [@CR7]\].

The World Health Organization recognized AMR as a global health problem and recommended that Member States should strengthen the knowledge and evidence base through AMR surveillance and research in the global action plan on AMR \[[@CR8]\]. Lack of AMR surveillance data contributes to underestimating the magnitude of AMR problem and halting the implementation of AMR control measures.

A surveillance study reported that the prevalence of rectal colonization by ESBL-producing Enterobacteriaceae among newly-hospitalized general medical patients in an Israel teaching hospital was only 8% \[[@CR9]\]. After two weeks of hospitalization, the prevalence of colonization increased to 21% \[[@CR9]\]. Surprisingly, the prevalence of rectal colonization by extended-spectrum beta-lactamase-producing Enterobacteriaceae in Thai community volunteers was remarkably high (32.0--66.5%) \[[@CR10], [@CR11]\].

Similar to ESBL-producing Enterobacteriaceae, the prevalence of *Pseudomonas aeruginosa* (PA) colonization varied across geographic locations. In a United States study, the prevalence of PA rectal colonization among intensive care unit (ICU) patients was 11.6% \[[@CR12]\]. However, a recent Spanish study found that the prevalence of rectal colonization by non-drug resistant PA and extensive drug resistant PA in ICU patients was 27.0% and 4.0%, respectively \[[@CR13]\].

Based on the data from a recent surveillance study performed in a medical ICU in Korea, active surveillance detected carbapenem-resistant-*Acinetobacter baumannii* (CR-AB) in 15.0% of patients, and approximately one-third of them later developed CR-AB infections \[[@CR14]\]. Similar to the Korean study, the prevalence of CR-AB colonization in ICU patients at a US tertiary hospital was 13.5% \[[@CR15]\].

Nasal colonization by methicillin-resistant *Staphylococcus aureus* (MRSA) has been widely investigated. The prevalence of MRSA nasal colonization varied from 4.1% in the US national surveillance in-patient data \[[@CR16]\] to 9.0% among newly-hospitalized patients in an Israel teaching hospital \[[@CR9]\]. Data on MRSA colonization at other sites in the body in addition to the nasal cavity is very limited.

Based on previous scientific evidence, the prevalence of MDR bacteria colonization varied across specific types of MDR bacteria, geographic regions and clinical settings \[community, hospital or long-term care facility (LTCF)\]. Although many studies have already investigated the prevalence of MDR bacteria colonization, most studies focused only on rectal or stool colonization by MDR gram-negative bacteria and nasal colonization by MRSA. Furthermore, these studies were not longitudinal studies that monitored changes in the prevalence of AMR bacteria colonization after hospitalization.

Given these considerations, we performed a prospective surveillance study for MDR bacteria colonization in hospitalized patients on admission and during hospitalization. The primary objective was to determine the prevalence of colonization by MDR bacteria in newly-hospitalized patients and the prevalence of new acquisition of MDR bacteria during hospitalization. The secondary objective was to identify risk factors for colonization by MDR bacteria and for new acquisition of MDR bacteria. Results from this study helped us determine the magnitude of AMR problem and the natural history of AMR colonization in hospitalized patients. Furthermore, the study could identify the patients at risk for MDR bacteria colonization who may subsequently develop infections due to these bacteria.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

During a 2-year study period (1 January 2013--31 December 2014), we performed a prospective surveillance study in eight general medical wards at Siriraj Hospital, which is a 2200-bed university hospital located in Bangkok, Thailand. The study protocol was approved by the Siriraj Institutional Review Board.

Study population {#Sec4}
----------------

The eligible subjects were all adults aged ≥18 years who had been hospitalized in general medical wards for less than 24 h. Subjects who were expected to be discharged or dead within 48 h or those with any contraindications for obtaining clinical specimens (i.e. a neutropenic patient (digital rectal examination or rectal swab culture was contraindicated), or having local infection at the site of surveillance culture) were excluded. Only subjects who agreed to participate and signed informed consent forms were enrolled.

Microbiological surveillance of AMR bacteria {#Sec5}
--------------------------------------------

Clinical specimens from four sites including the nasal cavity, throat, skin at the inguinal area and rectum or stool were obtained from each patient within 48 h after hospitalization (time-1). Clinical specimens were subsequently obtained on day 5 ± 1 of hospitalization (time-2) and then every 7 days until the patient left the hospital (time-3, time-4 and so on). All clinical specimens were transferred in Stuart transport medium to the Laboratory of Division of Infectious Diseases, Department of Medicine.

The targeted MDR bacteria were ESBL-producing Enterobacteriaceae*,* CR-PA, CR-AB and MRSA. MacConkey agar supplemented with ceftriaxone for the isolation of MDR gram-negative bacteria and Mannitol Salt agar for the isolation of staphylococci were used for inoculating the clinical specimens collected from all sites.

Species identification and antimicrobial susceptibility tests were performed according to the performance standards for antimicrobial susceptibility testing recommended by the Clinical and Laboratory Standards Institute 2013 \[[@CR17]\]. Species identification was performed using conventional biochemical tests. Identification of ESBL-producing bacteria was confirmed using the combination disc method. MRSA strains were determined using cefoxitin disc (30 mg) screening. Antimicrobial susceptibility testing was performed using the disc diffusion method.

Results of microbiology surveillance were directly reported to the study team and available (per request) for the service team (i.e. a responsible physician, an infectious disease consultant, etc.). However, there was no special infection control intervention for patients with colonization by target MDR-bacteria.

Data collection {#Sec6}
---------------

Medical records for the enrolled patients were reviewed for demographics, co-morbidities and clinical course. Data on any hospitalization, medication used, intervention and catheter use in the preceding 90 days prior to hospitalization were also obtained. Previous hospitalization included any stay at observation or emergency rooms for periodic monitoring and/or short-term treatment for longer than 24 h within 3 months prior to the index hospitalization.

Statistical analysis {#Sec7}
--------------------

Categorical variables were summarized by frequency and proportion, whereas continuous variables were summarised by mean, median, standard deviation and range as appropriate. The prevalence of colonization by MDR bacteria was reported as percentage with a 95% confidence interval (95% CI). Wilcoxon-type test for trend analysis was performed to identify an increasing trend of colonization over time after hospitalization.

Multivariate logistic analysis was performed to identify the risk factors for colonization by MDR bacteria (at any site) and for new acquisition of MDR bacteria (at any site). A separate model was built for each MDR pathogen including 1) ESBL-producing Enterobacteriaceae; 2) CR-PA and/or CR-AB and 3) MRSA. Primary analysis was performed to compare cases with the specific MDR pathogens to controls without the given pathogen. Additionally, we performed a secondary analysis by comparing cases with the specific MDR pathogen to controls without any colonization.

Any associated variable with a *p*-value ≤0.20 was entered in a forward stepwise manner into the model. Any associated variables with a *p*-value \< 0.20 was entered into the model. The likelihood ratio test was performed to confirm the model fit. For all calculations, a two-tailed *p*-value of \< 0.05 was considered statistically significant. All calculations were performed using STATA version 14.0 (Stata Corp, College Station, TX).

Results {#Sec8}
=======

Baseline characteristics of patients {#Sec9}
------------------------------------

During the study period, 487 patients were enrolled in the study as shown in Fig. [1](#Fig1){ref-type="fig"}. The baseline characteristics of patients prior to hospitalization are shown in Table [1](#Tab1){ref-type="table"}. Nearly half (45.4%) of the patients were male, with an average age of 61.7 ± 17.8 years. Previous hospitalization was documented in 43.3% of patients. Additionally, 11.0% and 1.2% of patients had been transferred from another hospital or a LTCF, respectively. Majority of patients (94.4%) had at least one underlying disease.Fig. 1Study flow chartTable 1Baseline characteristics of 487 patientsBaseline characteristics prior to hospitalizationn (%)Mean age ± SD (years)61.7 ± 17.8Male gender221 (45.4%)Mean length of hospital stay, days (±SD)14.5 ± 18.5Median length of hospital stay, days (range)10.0 (2.0--303.0)Previous hospitalization211 (43.3%)Transfer statusFrom another hospital56 (11.5%)From a long-term care facility6 (1.2%)Underlying diseasesAny underlying disease420 (86.2%)Hypertension290 (59.6%)Diabetes mellitus184 (37.8%)Cardiovascular diseases133 (27.3%)Cerebrovascular diseases97 (19.9%)Chronic liver diseases88 (18.0%)Chronic renal diseases64 (13.1%)Chronic lung diseases63 (12.9%)Malignancy87 (17.9%)Solid malignancy75 (15.4%)Hematologic malignancy12 (2.5%)Hematologic diseases47 (9.7%)Prior organ transplantation7 (1.4%)Receipt of any immunosuppressive agent within 90 days75 (15.4%)HIV infection16 (3.3%)Previous antibiotic exposure within 90 days after hospitalization Any antibiotic148 (30.4%) Penicillins19 (3.9%) Cephalosporins60 (12.3%) Carbapenems33 (6.8%) Beta-lactam/beta-lactamase inhibitors27 (5.5%) Fluoroquinolones46 (9.4%) Macrolides19 (3.9%) Others42 (8.6%)Previous use of indwelling catheters within 90 days Urinary catheter73 (15.0%) Nasogastric tube45 (9.2%)

The most common underlying disease was hypertension (59.6%), followed by diabetes mellitus (DM) (37.8%) and cardiovascular disease (27.3%). One-third (30.4%) of patients had previously been exposed to at least one type of antibiotics within the past 3 months. Approximately 15% of patients had a long-term urinary catheter inserted prior to hospitalization. The mean length of stay (LOS) was 14.5 ± 18.5 days, whereas the median LOS was 10 (2--303) days.

Colonization by MDR bacteria in newly-hospitalized patients {#Sec10}
-----------------------------------------------------------

The prevalence of colonization by MDR bacteria in newly-hospitalized patients stratified by MDR bacteria species and by colonization site is shown in Table [2](#Tab2){ref-type="table"}. Of the 487 patients evaluated, only 197 were free of colonization (40.5%). The rest (59.5%) were colonized by at least one specific MDR pathogen.Table 2Prevalence of colonization of MDR bacteria in newly-hospitalized patients (*N* = 487) stratified by the specific MDR bacteria and by the specimen collection siteMDR bacteriaAll sites, n (%)Nasal cavity, n (%)Throat, n (%)Inguinal area, n (%)Rectum, n (%)ESBL-producing Enterobacteriaceae254 (52.2%)13 (2.7%)42 (8.6%)80 (16.4%)232 (47.6%) *E. coli*206 (42.3%)5 (1.0%)14 (2.9%)58 (11.9%)189 (38.8%) *K. pneumoniae*81 (16.6%)9 (1.8%)31 (6.4%)29 (6.0%)60 (12.3%) Other Enterobacteriaceae8 (1.6%)01 (0.2%)3 (0.6%)7 (1.4%)*A. baumannii* Carbapenem-susceptible88 (18.0%)13 (2.7%)43 (8.8%)34 (7.0%)32 (6.6%) Carbapenem-resistant63 (12.9%)13 (2.7%)16 (3.3%)32 (6.6%)28 (5.8%)*P. aeruginosa* Carbapenem-susceptible33 (6.8%)10 (2.1%)11 (2.3%)18 (3.7%)12 (2.5%) Carbapenem-resistant23 (4.7%)9 (1.9%)18 (3.7%)2 (0.4%)6 (1.2%)*Staphylococcus aureus* Methicillin-susceptible49 (10.0%)29 (6.0%)21 (4.3%)8 (1.6%)11 (2.3%) Methicillin-resistant35 (7.2%)21 (4.3%)17 (3.5%)6 (1.2%)12 (2.5%)

More than half of the patients had ESBL-producing Enterobacteriaceae colonization in at least one body site, primarily in the rectum (47.6%) followed by the inguinal area (16.4%), throat (8.6%) and nasal cavity (2.7%). ESBL-producing *E. coli* (42.3%) were more prevalent than ESBL-producing *K. pneumoniae* (16.6%).

CR-PA was identified in only 4.7% of patients, primarily in the throat (3.7%). Baseline colonization by CR-AB was documented in 12.9% of patients, primarily in the inguinal area (6.6%) followed by the rectum (5.8%), throat (3.3%) and nasal cavity (2.7%).

MRSA was documented in 7.2% of patients, unlike MDR gram-negative bacteria, which primarily colonized in the nasal cavity (4.3%). The risk factors for baseline colonization by each MDR bacteria are reported in the next section.

Colonization by MDR bacteria during hospitalization {#Sec11}
---------------------------------------------------

Given that some patients were discharged or dead before subsequent clinical specimens were obtained, the number of follow-up specimens decreased over time. Collection of the subsequent specimens was successfully completed in 357 patients (73.3%) at time-2, 162 patients (33.3%) at time-3 and 53 patients (10.9%) at time-4. Overall colonization and colonization by all species of MDR bacteria showed an increasing trend over time as shown in Fig. [2](#Fig2){ref-type="fig"}. However, this increasing trend did not reach statistical significance in the test for trend analysis (all *p*-values \> 0.05). The details of colonization by MDR bacteria stratified by MDR bacteria species, colonization site and specimen collection time are shown in Table [3](#Tab3){ref-type="table"}. Due to the small number of new MDR bacteria acquisitions, we did not further investigate the risk factors for new acquisitions of these bacteria.Fig. 2Prevalence of colonization by MDR bacteria stratified by the specific MDR bacteria and by the specimen collection timeTable 3Prevalence of colonization on admission and during hospitalization stratified by the specific MDR bacteria, the surveillance culture site and the time of specimen collectionTimeAny site, (%)Nasal cavity, (%)Throat, (%)Inguinal area, (%)Rectum, (%)ESBL-producing Enterobacteriaceae Time-1 (*N* = 487)52.22.79.817.550.4 Time-2 (*N* = 357)51.83.415.117.546.2 Time-3 (*N* = 162)62.38.325.021.946.2 Time-4 (*N* = 53)71.712.028.627.153.8ESBL-producing *E. coli* Time-1 (*N* = 487)42.31.02.911.938.8 Time-2 (*N* = 357)41.21.33.710.934.3 Time-3 (*N* = 162)39.50.63.310.333.1 Time-4 (*N* = 53)41.52.04.116.732.7ESBL-producing *Klebsiella* spp. Time-1 (*N* = 487)16.61.96.45.912.3 Time-2 (*N* = 357)19.12.210.75.910.4 Time-3 (*N* = 162)34.67.119.79.719.4 Time-4 (*N* = 53)45.31.022.519.419.2CR-AB Time-1 (*N* = 487)6.82.12.33.72.5 Time-2 (*N* = 357)16.34.76.710.48.6 Time-3 (*N* = 162)27.88.313.215.510.0 Time-4 (*N* = 53)47.226.024.522.919.2CR-PA Time-1 (*N* = 487)4.71.63.70.41.2 Time-2 (*N* = 357)8.42.25.41.82.1 Time-3 (*N* = 162)12.35.87.23.23.8 Time-4 (*N* = 53)18.910.012.22.11.9MRSA Time-1 (*N* = 487)7.24.33.51.22.5 Time-2 (*N* = 357)7.33.12.21.12.2 Time-3 (*N* = 162)11.74.92.63.71.2 Time-4 (*N* = 53)18.97.55.73.71.8*Abbreviations: ESBL* Extended-Spectrum Beta-Lactamase, *CR-AB* Carbapenem-Resistant *Acinetobacter baumannii*, *CR-PA* Carbapenem-Resistant *Pseudomonas aeruginosa*, *MSSA* Methicillin-Susceptible *Staphylococcus aureus*, *MRSA* Methicillin-Resistant *Staphylococcus aureus*

Risk factors for colonization by ESBL-producing Enterobacteriaceae in hospitalized patients {#Sec12}
-------------------------------------------------------------------------------------------

The risk factors for baseline colonization by ESBL-producing Enterobacteriaceae in 254 patients compared with 233 patients without ESBL-producing Enterobacteriaceae colonization are shown in Table [4](#Tab4){ref-type="table"}. The independent risk factors from the primary multivariate analysis \[Odds Ratio (OR); 95% CI; *p-value*\] included underlying DM \[1.45;1.00--2.10; *p = 0.05*\] and previous exposure to cephalosporin \[2.00;1.13--3.54; *p = 0.02*\] as shown in Table [7](#Tab7){ref-type="table"}. Secondary analysis identified similar risk factors with a similar OR as shown in the Table [7](#Tab7){ref-type="table"}.Table 4Baseline characteristics prior to hospitalization for 254 patients (ESBL-producing Enterobacteriaceae) and 233 controls (no ESBL-producing Enterobacteriaceae)Baseline characteristicsESBL+\
(*N* = 254)ESBL-\
(*N* = 233)*p*-valueMean age ± SD (years)61.4 ± 18.261.9 ± 17.40.76Male gender120 (47.2%)101 (43.4%)0.39Previous hospitalization115 (45.3%)96 (41.2%)0.37Transfer statusFrom another hospital30 (11.8%)26 (11.2%)0.82From a long-term care facility4 (1.6%)2 (0.9%)0.47Underlying diseasesAny underlying disease225 (88.6%)195 (83.7%)0.12Hypertension115 (61.0%)135 (57.9%)0.49Diabetes mellitus106 (41.7%)78 (33.5%)0.06Cardiovascular disease74 (29.1%)59 (25.3%)0.35Cerebrovascular disease56 (22.0%)41 (17.6%)0.22Chronic liver disease43 (16.9%)45 (19.3%)0.50Chronic renal disease37 (14.6%)27 (11.6%)0.33Chronic lung disease32 (12.6%)41 (17.6%)0.82Malignancy46 (18.1%)41 (17.6%)0.88Solid malignancy42 (16.5%)33 (14.1%)0.47Hematologic malignancy4 (1.6%)8 (3.4%)0.19Hematologic diseases26 (10.2%)21 (9.0%)0.65Prior organ transplantation2 (0.8%)5 (2.2%)0.21Receipt of any immunosuppressive agent33 (13.0%)26 (11.2%)0.54HIV infection10 (3.9%)6 (2.6%)0.40Previous antibiotic exposure within 90 days after hospitalization Any antibiotic84 (33.1%)64 (27.5%)0.18 Penicillins12 (4.7%)7 (3.0%)0.33 Cephalosporins40 (15.8%)20 (8.6%)0.02 Carbapenems16 (6.3%)17 (7.3%)0.67 Beta-lactam/beta-lactamase inhibitors10 (3.9%)17 (7.3%)0.11 Fluoroquinolones26 (10.2%)20 (8.6%)0.53 Macrolides11 (4.3%)8 (3.4%)0.61 Others24 (9.5%)18 (7.7%)0.50Previous use of indwelling catheters Urinary catheter40 (15.8%)33 (14.2%)0.63 Nasogastric tube26 (10.2%)19 (8.2%)0.43

Risk factors for colonization by CR-PA and/or CR-AB in hospitalized patients {#Sec13}
----------------------------------------------------------------------------

Due to the small number of cases with baseline colonization by CR-AB and CR-PA, we combined data on colonization by these two MDR bacteria. A total of 49 patients (10.1%) had at least one clinical specimen that grew CR-PA and/or CR-AB at the baseline. The risk factors for baseline colonization by CR-PA and/or CR-AB in 49 patients compared with 438 patients without this colonization are shown in Table [5](#Tab5){ref-type="table"}. The independent risk factors identified in the primary analysis \[OR; 95% CI; *p-value*\] included previous hospitalization \[2.21;1.07--4.53; *p = 0.03*\], transfer from another hospital \[2.67;1.19--5.98; *p = 0.02*\] or a LTCF \[11.51;1.84--71.83; *p = 0.01*\], underlying cerebrovascular diseases \[2.90;1.37--6.16; *p = 0.005*\] and previous nasogastric tube use \[2.38;1.002--5.67; *p = 0.05*\]. Secondary analysis identified only three independent risk factors, specifically previous hospitalization, underlying cerebrovascular disease and previous nasogastric tube use, with slightly higher ORs. The results for both primary and secondary analyses are shown in Table [7](#Tab7){ref-type="table"}.Table 5Baseline characteristics prior to hospitalization for 49 patients (with CR-AB and/or CR-PA) and 438 controls (without CR-AB and CR-PA)Baseline characteristicsCR-AB and/or\
CR-PA (*n* = 49)No CR-AB and CR-PA (*n* = 438)*p*-valueMean age ± SD (years)66.7 ± 1861.1 ± 17.80.04Male gender18 (36.7%)203 (46.4%)0.20Previous hospitalization32 (65.3%)179 (40.9%)0.001Transfer statusFrom other hospital13 (26.5%)43 (9.8%)0.001From a long-term care facility4 (8.2%)2 (0.5%)\< 0.001Underlying diseasesAny underlying disease48 (98.0%)372 (84.9%)0.01Hypertension33 (67.4%)257 (58.7%)0.24Diabetes mellitus20 (40.8%)164 (37.4%)0.64Cardiovascular disease16 (32.7%)117 (26.7%)0.38Cerebrovascular disease23 (46.9%)74 (16.9%)\< 0.001Chronic liver disease9 (18.4%)79 (18.0%)0.95Chronic renal disease8 (16.3%)56 (12.8%)0.49Chronic lung disease7 (14.3%)56 (12.8%)0.77Malignancy7 (14.3%)80 (18.3%)0.49Solid malignancy7 (14.3%)68 (15.5%)0.82Hematologic malignancy012 (2.7%)0.24Hematologic diseases6 (12.2%)41 (9.4%)0.52Prior organ transplantation1 (2.0%)6 (1.4%)0.71Receipt of any immunosuppressive agent6 (12.2%)- 53 (12.1%)0.98HIV infection1 (2.0%)15 (3.4%)0.61Previous antibiotic exposure within 90 days after hospitalization Any antibiotic26 (53.1%)122 (27.9%)\< 0.001 Penicillins1 (2.0%)18 (4.1%)0.48 Cephalosporins10 (20.4%)50 (11.4%)0.07 Carbapenems9 (18.4%)24 (5.5%)0.001 Beta-lactam/beta-lactamase inhibitors7 (14.3%)20 (4.6%)0.005 Fluoroquinolones8 (16.3%)38 (8.7%)0.08 Macrolides4 (8.2%)15 (3.4%)0.10 Others8 (16.3%)34 (7.8%)0.04Previous use of indwelling catheters Urinary catheter19 (38.8%)54 (12.3%)\< 0.001 Nasogastric tube16 (32.7%)29 (6.6%)\< 0.001

Risk factors for colonization by MRSA in hospitalized patients {#Sec14}
--------------------------------------------------------------

Of the 487 enrolled patients, 35 (7.2%) had at least one clinical specimen that grew MRSA at the baseline. Baseline characteristics for the 35 patients with MRSA colonization and 452 patients without MRSA colonization are shown in Table [6](#Tab6){ref-type="table"}. Independent risk factors for baseline colonization by MRSA \[OR; 95% CI; *p-value*\] were previous fluoroquinolone exposure \[2.76; 1.13--6.74; *p = 0.03*\] and previous nasogastric tube use \[6.60; 1.13--6.74; *p \< 0.001*\]. Stronger association between these two factors and baseline colonization by MRSA was documented in secondary analysis as shown in Table [7](#Tab7){ref-type="table"}.Table 6Baseline characteristics prior to hospitalization for 35 patients (with MRSA) and 452 controls (without MRSA)Baseline characteristicsMRSA (n = 35)No MRSA (*n* = 452)*p*-valueMean age ± SD (years)66.7 ± 20.161.3 ± 17.60.09Male gender22 (62.9%)244 (54.0%)0.31Previous hospitalization23 (65.7%)188 (41.6%)0.006Transfer status From other hospital5 (14.3%)52 (11.3%)0.59 From a long-term care facility06 (1.3%)1.00Underlying diseasesAny underlying disease31 (88.6%)389 (86.1%)0.68Hypertension22 (62.9%)268 (59.3%)0.68Diabetes mellitus13 (37.1%)172 (38.1%)0.92Cardiovascular disease12 (34.3%)121 (26.8%)0.34Cerebrovascular disease15 (42.9%)82 (18.1%)\< 0.001Chronic liver disease5 (14.3%)83 (18.4%)0.55Chronic renal disease3 (8.6%)61 (13.4%)0.60Chronic lung disease5 (14.3%)58 (12.8%)0.79Malignancy6 (17.1%)81 (17.9%)0.91Solid malignancy5 (14.3%)70 (15.5%)0.85Hematologic malignancy1 (2.9%)11 (2.4%)0.60Hematologic diseases3 (8.6%)44 (9.7%)1.00Prior organ transplantation07 (1.6%)1.00Receipt of any immunosuppressive agent4 (11.4%)55 (12.2%)1.00HIV infection1 (2.9%)15 (3.3%)1.00Previous antibiotic exposure within 90 days after hospitalization Any antibiotic19 (54.3%)129 (28.5%)0.001 Penicillins2 (5.7%)17 (3.8%)0.64 Cephalosporins6 (17.1%)54 (12.0%)0.37 Carbapenems6 (17.1%)27 (6.0%)0.01 Beta-lactam/beta-lactamase inhibitor5 (14.3%)22 (4.9%)0.02 Fluoroquinolones9 (25.7%)37 (8.2%)0.001 Macrolides2 (5.7%)17 (3.8%)0.64 Others5 (14.3%)37 (8.2%)0.22Previous use of indwelling catheters Urinary catheter13 (37.1%)32 (7.1%)\< 0.001 Nasogastric tube13 (37.1%)60 (13.3%)\< 0.001Table 7Independent risk factors for baseline colonization by ESBL-producing Enterobacteriaceae, CR-AB and/or CR-PA and MRSA from the primary and secondary analysesVariablesAdjusted OR \[95% CI; *p-value*\]Primary Analysis (Case vs non-case)Secondary Analysis (Case vs No MDR)*1.* ESBL-producing *Enterobacteriaceae*Case (*n* = 254) vs. non-case (*n* = 233)Case (*n* = 254) vs. no MDR (*n* = 197) Underlying diabetes mellitus1.45 \[1.00--2.10; *p = 0.05*\]1.49 \[1.01--2.20; *p = 0.05*\] Previous cephalosporin exposure2.00 \[1.13--3.54; *p = 0.02*\]2.06 \[1.11--3.81; *p = 0.02*\]*2.* CR-AB and/or CR-PACase (*n* = 49) vs. non-case (*n* = 438)Case (*n* = 49) vs. no MDR (*n* = 197) Previous hospitalization2.21 \[1.07--4.53; *p = 0.03*\]2.96 \[1.40--6.26; *p = 0.004*\] Transfer from another hospital2.67 \[1.19--5.98; *p = 0.02*\]... Transfer from a LTCF11.51 \[1.84--71.83; *p = 0.01*\]... Underlying cerebrovascular disease2.90 \[1.37--6.16; *p = 0.005*\]2.68 \[1.08--6.64; *p = 0.03*\] Previous nasogastric tube use2.38 \[1.002--5.67; *p = 0.05*\]4.13 \[1.27--13.47; *p = 0.02*\]*3.* MRSACase (*n* = 35) vs. non-case (*n* = 452)Case (*n* = 35) vs. no MDR (*n* = 197) Previous fluoroquinolone exposure2.76 \[1.13--6.74; *p = 0.03*\]3.85 \[1.26--11.80; *p = 0.02*\] Previous use of nasogastric tube6.60 \[1.13--6.74; *p \< 0.001*\]12.86 \[4.47--36.97; *p \< 0.001*\]

Discussion {#Sec15}
==========

The present study revealed a remarkably high prevalence of baseline colonization by ESBL-producing Enterobacteriaceae compared with the prevalence from the Israel study (52.2% vs 8%) \[[@CR9]\]. However, our baseline prevalence for faecal colonization by ESBL-producing Enterobacteriaceae (47.6%) was comparable with the prevalence of ESBL colonization among Thai community volunteers (32.0--66.5%) \[[@CR10], [@CR11]\].

Two important characteristics, namely DM and previous cephalosporin use, were identified as the independent risk factors for baseline colonization by ESBL-producing Enterobacteriaceae in this study. These findings were previously documented in many studies \[[@CR9], [@CR10]\]. Underlying DM may be a proxy for recurrent infections, previous antibiotic use and previous hospitalization \[[@CR10], [@CR18], [@CR19]\]. Previous exposure to cephalosporin would result in selective pressure against non-ESBL-producing pathogens to become resistant to cephalosporin, leading to colonization in the patients \[[@CR20]\].

This study revealed the comparable prevalence of CR-PA colonization (4.7%) compared with the results from the Spanish ICU study (4.0%) \[[@CR13]\]. Additionally, the prevalence of CR-AB colonization (12.9%) was similar to the findings from previous studies performed in ICU patients (13.5--15.0%) \[[@CR14], [@CR15]\]. Although our study included only hospitalized patients in general medical wards, these patients were sicker than those hospitalized in a general medical ward in developed countries due to resource limitations. These statements could be confirmed due to a very high proportion of patients with co-morbidities (\> 80%). Furthermore, approximately 40% of our enrolled patients had been previously hospitalized and more than 30% had a previous history of antibiotic exposure. These factors may explain the comparative prevalence of CR-PA and CR-AB colonization.

The independent risk factors for CR-AB and/or CR-PA colonization identified in this study were underlying cerebrovascular disease (CVA), previous hospitalization, transfer from another hospital or a LTCF and previous nasogastric tube use. Previous hospitalization and transfer from another hospital or a LTCF are well known risk factors for colonization by MDR bacteria. Neurologic disease was previously documented as an independent risk factor for PA colonization \[[@CR12]\]. Furthermore, underlying CVA may be a proxy of aspiration pneumonia, previous nasogastric tube use, functional disability and previous hospitalization \[[@CR21]\].

Our results for the baseline prevalence of MRSA colonization (7.2%) were comparable with results from previous studies \[[@CR9], [@CR16]\]. Significant risk factors for MRSA colonization identified in our study included previous fluoroquinolone exposure and previous nasogastric tube use. Previous fluoroquinolone exposure is well documented as an independent risk factor for MRSA colonization in many observational studies \[[@CR22], [@CR23]\]. Recent use of nasogastric tube was previously identified to be a significant risk factor for MRSA nasal colonization in end-stage renal disease patients \[[@CR24]\].

The present study had several strengths. It was specifically designed to determine the prevalence of MDR bacteria colonization at various sites (nasal cavity, throat, skin at the inguinal area and rectum) and by a variety of important MDR bacteria (ESBL-producing Enterobacteriaceae, CR-PA, CR-AB and MRSA). Additionally, clinical specimens were collected at various time points to capture additional acquisition rates of colonization by MDR bacteria after hospitalization. Furthermore, we thoroughly collected all clinical characteristics that may be associated with baseline colonization by MDR bacteria.

The present study had some limitations. First, there was a small number of follow-up cultures, with only 53 specimens collected at time-4. Given that sicker patients are more likely to have a longer LOS with more collected clinical specimens, the prevalence of colonization after hospitalization may not represent the true prevalence. Second, the study results may be applicable to only tertiary care university hospitals. As we mentioned before, patients in our study were relatively sicker than those hospitalized at a general medical ward in developed countries.

Conclusion {#Sec16}
==========

The prevalence of baseline colonization by ESBL-producing Enterobacteriaceae was relatively high, whereas the prevalence of baseline colonization by CR-PA, CR-AB and MRSA was comparable with the results from previous studies in other geographical locations. There was a slightly increasing trend of MDR bacteria colonization by all important pathogens after hospitalization. However, these observations did not reach statistical significance. Previous antibiotic use and previous nasogastric tube use were the common risk factors for various species of MDR pathogens. The documented risk factors from our study may be used to identify patients who are at a risk for MDR bacterial infection. A study with a larger sample size would be needed to identify the risk factors for acquiring new MDR colonization after hospitalization. Measures to prevent or delay colonization by MDR bacteria in hospitalized patients should be employed.

AMR

:   Antimicrobial resistance

CR-AB

:   Carbapenem-resistant-*A. baumannii*

CR-PA

:   Carbapenem-resistant-*P. aeruginosa*

CVA

:   Cerebrovascular disease

DM

:   Diabetes mellitus

ESBL

:   Extended-spectrum beta-lactamase-producing

HIV

:   Human immunodeficiency virus

ICU

:   Intensive care unit

LTCF

:   Long-term care facility

MDR

:   Multidrug-resistant

SD

:   Standard deviation
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